Kawachi S, Shimabukuro Z, Aoyama A, Yano T, Hasegawa K, Tsuboi E, Niitani H
Gan To Kagaku Ryoho. 1987 Aug;14(8):2469-74.
Serum neuron-specific enolase (NSE) was measured in 105 patients with lung cancer without prior therapy. Increasing serum levels of NSE were observed in 84% of cases of small cell lung cancer (SCLC). 11% of adenocarcinomas, 18.5% of squamous cell carcinomas and 37.5% of large cell carcinomas. Serum NSE levels changed in parallel with the effect of initial treatment. Although two of 5 patients with SCLC, in whom serial NSE levels were measured after treatment, showed elevation of serum NSE levels before clinical relapse, elevated serum NSE levels were not observed in 3 patients at clinical relapse. These data seem to suggest that measurement of serial NSE is useful for predicting relapse prior to clinical recognition. However, it still remains an important point to carry out clinical general surveillance for relapse.
对105例未经前期治疗的肺癌患者检测了血清神经元特异性烯醇化酶（NSE）。在84%的小细胞肺癌（SCLC）病例中观察到血清NSE水平升高。腺癌患者中有11%、鳞状细胞癌患者中有18.5%以及大细胞癌患者中有37.5%出现血清NSE水平升高。血清NSE水平随初始治疗效果平行变化。在5例治疗后进行NSE水平系列检测的SCLC患者中，有2例在临床复发前血清NSE水平升高，但另外3例患者在临床复发时未观察到血清NSE水平升高。这些数据似乎表明，系列NSE检测有助于在临床确诊复发之前进行预测。然而，对复发进行临床全面监测仍然是一个要点。
